Back to top
more

Cencora, Inc. (COR)

(Real Time Quote from BATS)

$237.56 USD

237.56
360,084

-0.77 (-0.32%)

Updated Jun 26, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis

Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.

Why You Should Add Inspire Medical (INSP) to Your Portfolio

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays

PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.

GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imaging

GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.

Here's Why You Should Retain Chemed (CHE) Stock for Now

Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Revvity's (RVTY) Launch to Boost Pharma-Contract Partner Tie-Up

Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.

Philips (PHG) Agrees to a Consent Decree With DOJ and FDA

Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.

GE HealthCare (GEHC) to Showcase Enhanced Breast Cancer Imaging

GE HealthCare's (GEHC) latest breast cancer detection technology is likely to enhance the detection and diagnosis of breast cancer and improve patient outcomes.

DexCom (DXCM), MD Revolution Unite to Boost Diabetes Management

DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.

Is Artivion (AORT) Outperforming Other Medical Stocks This Year?

Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.

Here's Why Cencora (COR) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail

Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.

Here's Why Cencora (COR) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Reasons to Hold The Cooper Companies (COO) in Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?

Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.

Align Technology (ALGN) Up 20.5% YTD: Will the Rally Continue?

Investors are optimistic about Align Technology (ALGN) driven by geographic expansion and upbeat guidance.

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Boston Scientific (BSX) Faces Rising Costs, Competition

With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.

Why You Should Retain Inari Medical (NARI) Stock for Now

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.